Contact Us
Find A Doctor

Eye001 Injections in AMD Patients Study

Principal Investigator:

Richard B. Rosen, M.D.

Enrollment Status:



To establish the safety and efficacy of intravitreal injections of EYE001 versus sham injections in patients with subfoveal choroidal neovascularization secondary to AMD. This is a Phase II/III randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups.


MACUGEN (Pegaptanib Sodium) treatment given every 6 weeks for up to 2 years has been shown to significantly reduce the risk of moderate vision loss in patients with all types of wet AMD. Data suggests that patients who had early wet AMD and were treated with MACUGEN had improved vision outcomes than those who started treatment later. These kinds of results highlight the importance of beginning treatment before wet AMD becomes advanced and routine activities become difficult.

For more information:



Contact Us

Dr. Richard Rosen, Principal InvestigatorTel: (212) 979-4284

Katy Tai, Research ManagerTel: (212) 979-4251

Address310 E. 14th StreetNew York, NY 10003

View all locations